|
Avutometinib Clinical Trials
10 actively recruiting trials across 7 locations
No change since May 2026
Also known as: CH-5126766, CH5126766, CKI-27, R-7304, RG 7304 +8 more
Pipeline
Phase 1: 1Phase 2: 6Phase 3: 1Phase 1/2: 2
Top Sponsors
- Memorial Sloan Kettering Cancer Center3
- Washington University School of Medicine1
- Verastem, Inc.1
- University of Utah1
- Ryan H. Moy, MD, PhD1
Indications
- Cancer10
- Low-Grade Serous Ovarian Cancer2
- Optic Pathway Gliomas1
- MAP Kinase Family Gene Mutation1
- CNS Tumor, Childhood1
Atlanta, Georgia3 trials
A Study of Avutometinib for People With Solid Tumor Cancers
Children's Healthcare of Atlanta (Data Collection Only)
Phase 1
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
Emory Winship Cancer Institute
Phase 2
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University Hospital Midtown
Phase 2
Other1 trial
Phoenix, Arizona1 trial
Iowa City, Iowa1 trial
St Louis, Missouri1 trial
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
Phase 2
Basking Ridge, New Jersey1 trial
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Phase 2
New York, New York1 trial
Avutometinib and Defactinib in Diffuse Gastric Cancer
Columbia University Irving Medical Center
Phase 2
Houston, Texas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.